Related Experiment Videos
Antiplatelet therapy: glycoprotein IIb/IIIa receptor antagonists
S Kessler1, D Kessler, W H Frishman
1Department of Medicine, New York Medical College, Valhalla 10595, USA.
Drugs of Today (Barcelona, Spain : 1998)
|September 16, 2003
Summary
Glycoprotein IIb/IIIa antagonists are powerful drugs that prevent platelet aggregation. These intravenous medications are used for high-risk angioplasty and unstable coronary syndromes, with oral forms now in trials.
Area of Science:
- Cardiovascular pharmacology
- Hematology
- Drug development
Background:
- Platelet aggregation is a key process in thrombotic events.
- Glycoprotein IIb/IIIa receptors play a critical role in platelet aggregation.
Purpose of the Study:
- To summarize the role and formulations of glycoprotein IIb/IIIa antagonists.
- To highlight their clinical applications and ongoing research.
Main Methods:
- Review of existing literature on glycoprotein IIb/IIIa antagonists.
- Analysis of current clinical trial data for oral agents.
Main Results:
- Glycoprotein IIb/IIIa antagonists are effective inhibitors of platelet aggregation.
- Intravenous formulations are established for specific cardiovascular conditions.
- Orally active agents are under investigation.
Conclusions:
- Glycoprotein IIb/IIIa antagonists represent a significant advancement in antiplatelet therapy.
- Further development of oral agents may expand therapeutic options for cardiovascular diseases.